

Ref no: 308210121  
From: Commercial  
Date: 21/01/21  
Subject: biologic and biosimilar products within Rheumatology

## REQUEST & RESPONSE

Wilmington Healthcare is analysing the usage of biologic and biosimilar products within Rheumatology. I fully appreciate the current pressures the NHS is facing, but it would be really helpful if you could answer the following two questions:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia]: **32**
- Adalimumab [Humira]: **41**
- Adalimumab Biosimilars: **163**
- Apremilast [Otezla]: **<5**
- Baricitinib [Olumiant]: **82**
- Certolizumab [Cimzia]: **23**
- Etanercept [Enbrel]: **49**
- Etanercept Biosimilars: **103**
- Filgotinib [Jyseleca]: **0**
- Golimumab [Simponi]: **36**
- Infliximab [Remicade]: **<5**
- Infliximab Biosimilars: **13**
- Ixekizumab [Taltz]: **0**
- Rituximab [MabThera]: **<5**
- Rituximab Biosimilars: **21**
- Sarilumab [Kevzara]: **0**
- Secukinumab [Cosentyx]: **17**
- Tocilizumab [Ro Actemra]: **41**
- Tofacitinib [Xeljanz]: **26**
- Upadacitinib [Rinvoq]: **0**
- Ustekinumab [Stelara]: **7**

### **NB**

**We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be**

**re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018.**

**In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.**

**Q2. Could you please provide the numbers of patients treated for Rheumatoid Arthritis ONLY in the last 3 months with the following drugs:**

- Abatacept [Orencia]
- Adalimumab [Humira]
- AdalimumabBiosimilars
- Baricitinib [Olumiant]
- Certolizumab [Cimzia]
- Etanercept [Enbrel]
- EtanerceptBiosimilars
- Filgotinib [Jyseleca]
- Golimumab [Simponi]
- Infliximab [Remicade]
- Infliximab Biosimilars
- Rituximab [MabThera]
- Rituximab Biosimilars
- Sarilumab [Kevzara]
- Tocilizumab [Ro Actemra]
- Tofacitinib [Xeljanz]
- Upadacitinib [Rinvoq]

**St Helens and Knowsley Teaching Hospital NHS Trust does not hold this information.**